Orthocell Limited (ASX:OCC)
Australia
· Delayed Price · Currency is AUD 0.800
-0.085 (-9.60%)
At close: Mar 9, 2026
Orthocell Revenue
Orthocell had revenue of 5.42M AUD in the half year ending December 31, 2025, with 285.47% growth. This brings the company's revenue in the last twelve months to 9.33M, up 23.65% year-over-year. In the fiscal year ending June 30, 2025, Orthocell had annual revenue of 7.55M with 42.05% growth.
Revenue (ttm)
9.33M
Revenue Growth
+23.65%
P/S Ratio
23.26
Revenue / Employee
n/a
Employees
n/a
Market Cap
217.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.55M | 2.24M | 42.05% |
| Jun 30, 2024 | 5.32M | 1.07M | 25.27% |
| Jun 30, 2023 | 4.24M | 2.71M | 177.01% |
| Jun 30, 2022 | 1.53M | 513.76K | 50.47% |
| Jun 30, 2021 | 1.02M | 298.44K | 41.48% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dimerix | 7.42M |
| Tetratherix | 2.00M |
| Starpharma Holdings | 14.58M |
| Actinogen Medical | 7.36M |
| Recce Pharmaceuticals | 974.56K |
| Racura Oncology | 3.48M |
| Botanix Pharmaceuticals | 21.92M |
| Island Pharmaceuticals | 62.85K |
Orthocell News
- 7 weeks ago - The company repairing human bone with Kimberley pearl shells - The Australian Financial Review
- 5 months ago - Perth biotech Orthocell targets US growth with $25m capital injection - The Australian Financial Review
- 1 year ago - Perth’s billionaire set is piling into this little-known medtech - The Australian Financial Review